|
Ductal carcinoma in situ (DCIS) is becoming increasingly common, accounting for 25%–30% of newly diagnosed cases of breast cancer (1). The comedo type represents about 40% of the cases and carries the worst prognosis (2). The subsequent incidence of recurrence in patients presenting previously with comedo DCIS was...
|
jnci.oxfordjournals.org/cgi/content/full/92/14/1185A
|
|
|
|
|
BACKGROUND: Ductal carcinoma in situ (DCIS) represents 20%-30% of breast cancers detected by clinical screening (i.e., mammography). More than 50% of DCIS lesions may be ... RESULTS: Initial levels of cell proliferation were approximately 10- fold higher in 10 specimens with estrogen receptor-negative, comedo (i.e.,
|
jnci.oxfordjournals.org/cgi/content/short/89/14/1059
|
|
|
Mammary ductal carcinoma with comedo pattern in a rhesus macaque. ... Mammary ductal carcinoma with comedo pattern in a rhesus macaque.Mammary ductal carcinoma with comedo pattern in a rhesus macaque.
|
www.ncbi.nlm.nih.gov/pubmed/16050665
|
|
Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death. ... Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death.Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death.
|
www.ncbi.nlm.nih.gov/pubmed/18787417
|
|
Diagnosis: Ductal carcinoma in situ (DCIS), comedo subtype. ... Discussion: Ductal carcinoma DCIS is a malignant intraductal epithelial proliferation, which confined by the basement membrane. It manifests with a variety of histologic patterns and can be broadly divided into comedo and noncomedo subtypes.
|
www.uhrad.com/mamarc/mam016.htm
|
|
Franks et al., 2003b S.J. Franks, H.M. Byrne, H. Mudhar, J.C.E. Underwood and C.E. Lewis, Modelling the growth of comedo ductal carcinoma in situ, Math. ...
|
linkinghub.elsevier.com/retrieve/pii/S0022519304004205
|
|
Tetrahedron radiography of the microcalcifications of comedo ductal carcinoma in situ: three-dimensional assessment of surgical excision ...
|
linkinghub.elsevier.com/retrieve/pii/0960977695900063
|
|
BACKGROUND: Results of the National Surgical Adjuvant Breast Project B-24 trial indicate that adjuvant tamoxifen therapy is of benefit only in oestrogen receptor (ER)- positive ductal carcinoma in situ (DCIS). In the UK, ER status is not routinely determined in DCIS.
|
www.medscape.com/medline/abstract/15736216
|
|
Ductal carcinoma in-situ (comedo-type) with central microcalcification. Histologic section. Hematoxylin and Eosin stain ... Ductal carcinoma in-situ (comedo-type). Fine-needle aspiration. Papanicolaou stain...
|
www.gfmer.ch/selected_images_v2/detail_list.php?cat1=2&...
www.gfmer.ch/selected_images_v2/detail_list.php?cat1=2&cat3=67&stype=d
|
|
